Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer's disease assessment

被引:7
作者
Weber, Darren M. [1 ]
Taylor, Steven W. [1 ]
Lagier, Robert J. [1 ]
Kim, Jueun C. [1 ]
Goldman, Scott M. [1 ]
Clarke, Nigel J. [1 ]
Vaillancourt, David E. [2 ]
Duara, Ranjan [2 ,3 ]
McFarland, Karen N. [4 ]
Wang, Wei-en [2 ]
Golde, Todd E. [4 ,5 ]
Racke, Michael K. [1 ]
机构
[1] Quest Diagnost Nichols Inst, San Juan Capistrano, CA 92675 USA
[2] Univ Florida, Dept Appl Physiol & Kinesiol, Gainesville, FL USA
[3] Wien Ctr Alzheimers Dis & Memory Disorders, Mt Sinai Med Ctr, Miami Beach, FL USA
[4] Univ Florida, Ctr Translat Res Neurodegenerat Dis, Alzheimers Dis Res Ctr ADRC 1Florida, Florida Alzheimers Dis Res Ctr ADRC 1, Gainesville, FL USA
[5] Emory Univ, Emory Ctr Neurodegenerat Dis, Dept Pharmacol & Chem Biol, Dept Neurol, Atlanta, GA USA
来源
FRONTIERS IN NEUROLOGY | 2024年 / 15卷
基金
美国国家卫生研究院;
关键词
Alzheimer's disease; beta-amyloid; blood biomarkers; LC-MS/MS; PET; prescreening; AMYLOID-BETA; COGNITIVE IMPAIRMENT; PERFORMANCE; TAU; INDIVIDUALS; POPULATION; DIAGNOSIS; GENOTYPE; VALIDITY; COHORT;
D O I
10.3389/fneur.2024.1364658
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction Plasma A beta 42/40 ratio can help predict amyloid PET status, but its clinical utility in Alzheimer's disease (AD) assessment is unclear.Methods A beta 42/40 ratio was measured by LC-MS/MS for 250 specimens with associated amyloid PET imaging, diagnosis, and demographic data, and for 6,192 consecutive clinical specimens submitted for A beta 42/40 testing.Results High diagnostic sensitivity and negative predictive value (NPV) for A beta-PET positivity were observed, consistent with the clinical performance of other plasma LC-MS/MS assays, but with greater separation between A beta 42/40 values for individuals with positive vs. negative A beta-PET results. Assuming a moderate prevalence of A beta-PET positivity, a cutpoint was identified with 99% NPV, which could help predict that AD is likely not the cause of patients' cognitive impairment and help reduce PET evaluation by about 40%.Conclusion High-throughput plasma A beta 42/40 LC-MS/MS assays can help identify patients with low likelihood of AD pathology, which can reduce PET evaluations, allowing for cost savings.
引用
收藏
页数:12
相关论文
共 52 条
  • [1] Anderson J, 2022, AM FAM PHYSICIAN, V105, P79
  • [2] [Anonymous], of Precision of Quantitative Measurement Procedures
  • [3] Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer's disease
    Bellaver, Bruna
    Povala, Guilherme
    Ferreira, Pamela C. L.
    Ferrari-Souza, Joao Pedro
    Leffa, Douglas T.
    Lussier, Firoza Z.
    Benedet, Andrea L.
    Ashton, Nicholas J.
    Triana-Baltzer, Gallen
    Kolb, Hartmuth C.
    Tissot, Cecile
    Therriault, Joseph
    Servaes, Stijn
    Stevenson, Jenna
    Rahmouni, Nesrine
    Lopez, Oscar L.
    Tudorascu, Dana L.
    Villemagne, Victor L.
    Ikonomovic, Milos D.
    Gauthier, Serge
    Zimmer, Eduardo R.
    Zetterberg, Henrik
    Blennow, Kaj
    Aizenstein, Howard J.
    Klunk, William E.
    Snitz, Beth E.
    Maki, Pauline
    Thurston, Rebecca C.
    Cohen, Ann D.
    Ganguli, Mary
    Karikari, Thomas K.
    Rosa-Neto, Pedro
    Pascoal, Tharick A.
    [J]. NATURE MEDICINE, 2023, 29 (07) : 1775 - +
  • [4] The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review
    Brand, Abby L. L.
    Lawler, Paige E. E.
    Bollinger, James G. G.
    Li, Yan
    Schindler, Suzanne E. E.
    Li, Melody
    Lopez, Samir
    Ovod, Vitaliy
    Nakamura, Akinori
    Shaw, Leslie M.
    Zetterberg, Henrik
    Hansson, Oskar
    Bateman, Randall J. J.
    [J]. ALZHEIMERS RESEARCH & THERAPY, 2022, 14 (01)
  • [5] Performance of plasma Aβ42/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status
    Bun, Shogyoku
    Ito, Daisuke
    Tezuka, Toshiki
    Kubota, Masahito
    Ueda, Ryo
    Takahata, Keisuke
    Moriguchi, Sho
    Kurose, Shin
    Momota, Yuki
    Suzuki, Natsumi
    Morimoto, Ayaka
    Hoshino, Yuka
    Seki, Morinobu
    Mimura, Yu
    Shikimoto, Ryo
    Yamamoto, Yasuharu
    Hoshino, Takayuki
    Sato, Yoshiaki
    Tabuchi, Hajime
    Mimura, Masaru
    [J]. ALZHEIMERS RESEARCH & THERAPY, 2023, 15 (01)
  • [6] Exploratory Study of Apolipoprotein E ε4 Genotype and Risk of Alzheimer's Disease in Mexican Hispanics
    Campos, Melissa
    Edland, Steven D.
    Peavy, Guerry M.
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2013, 61 (06) : 1038 - 1040
  • [7] The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort
    Caroli, A.
    Frisoni, G. B.
    [J]. NEUROBIOLOGY OF AGING, 2010, 31 (08) : 1263 - 1274
  • [8] Reference intervals for plasma amyloid-β, total tau, and phosphorylated tau181 in healthy elderly Chinese individuals without cognitive impairment
    Chen, Jingshan
    Zhao, Xue
    Zhang, Wenyan
    Zhang, Tianxiang
    Wu, Siting
    Shao, Jinghao
    Shi, Fu-Dong
    [J]. ALZHEIMERS RESEARCH & THERAPY, 2023, 15 (01)
  • [9] CLSI, 2021, CLSI implementation guide EP15-Ed3-IG1, V1st
  • [10] CLSI, 2018, EP07 CLSI